ERBB2 and breast carcinoma: Of note, the majority of participants in SANDPIPER (97.0%) were cyclin‐dependent kinase 4/6 (CDK4/6) inhibitor‐naïve given that they were randomized between 2015 and 2017 [6], which coincided with the initial approvals of CDK4/6 inhibitors for HR+, HER2− breast cancer treatment.